Cohance Lifesciences, backed by Advent International, is set to invest Rs 110 crore to expand its capabilities in Hyderabad, India, and New Jersey, USA.

The plan includes USD 10 million (approx. Rs 87 crore) for enhancing cGMP bioconjugation capabilities at its US-based subsidiary, NJ Bio, and Rs 23 crore for a new cGMP oligonucleotide building block manufacturing facility in Hyderabad. The unit will handle advanced chemistries such as modified nucleosides and locked nucleic acids (LNA), scaling from laboratory to commercial production, with GMP capacity up to 700 kg annually and scope for expansion.

Integrated with a pilot plant for early-stage synthesis, it will serve innovators developing oligonucleotide-based therapeutics. The US investment will strengthen fully integrated antibody-drug conjugate (ADC) solutions. Together, these expansions support Cohance’s goal of becoming a preferred partner for emerging modalities, offering end-to-end support from early development to late-phase clinical supply. 

Executive Chairman Vivek Sharma emphasized that the move aligns with the company’s strategy to deliver speed, quality, and flexibility in next-generation therapeutics.